aplastic anemia | Page 81 | Aplastic Anemia & MDS International Foundation Return to top.

aplastic anemia

Survival After Immunosuppressive Therapy in Children with Aplastic Anemia

Author(s): 
Nair V, Sondhi V, Sharma A, Das S, Sharma S
Primary Author: 
Nair V
Journal Title: 
Indian Pediatr
Original Publication Date: 
Oct 2011

OBJECTIVE:

To determine the survival of children ?18y, treated with immunosuppresive therapy (IST) using equine antithymocyte globulin (e-ATG) and cyclosporine(CsA).
DESIGN:

Prospective data entry as per a specified format.
SETTING:

Tertiary care hospital.
PATIENTS:

From January 1998 to December 2009, 40 children were diagnosed with acquired aplastic anemia; 33 patients, who received IST, were analyzed. 31 children (94%) received one course of e-ATG and CsA. 2 patients (6%) received two courses of ATG.
INTERVENTION:

Immunosuppressive therapy using equine ATG and cyclosporine.
MAIN OUTCOME MEASURES:

Overall response and overall survival.
RESULTS:

Bone Marrow Disease(s): 

Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

Author(s): 
Calado RT, Cooper JN, Padilla-Nash HM, Sloand EM, Wu CO, Scheinberg P, Ried T, Young NS
Primary Author: 
Calado RT
Journal Title: 
Leukemia
Original Publication Date: 
Oct 2011

In cell and animal models,

Bone Marrow Disease(s): 

Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia.

Author(s): 
Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y, Kato M, Sanada M, Morishima Y, Hosokawa K, Sasaki Y, Ohtake S, Ogawa S, Nakao S.
Primary Author: 
Katagiri T
Journal Title: 
Blood
Original Publication Date: 
Sep 2011

Idiopathic

Bone Marrow Disease(s): 

Nutritional support in the treatment of aplastic anemia

Author(s): 
Jia L, Yu J, He L, Wang H, Jiang L, Miao X, Wu W, Yang P
Primary Author: 
Jia L
Journal Title: 
Nutrition
Original Publication Date: 
May 2011

OBJECTIVE:

Whether a specific nutritional support promotes healing of aplastic anemia (AA) patients is still unclear. Therefore, we explored the potential of a high-nucleotide, arginine, and micronutrient nutritional supplement on the nutritional rehabilitation of AA mice.
METHODS:

The BALB/c AA mice model was treated with hypodermic injections of acetylphenylhydrazine (100 mg/kg), x-ray (2.0 Gy), and intraperitoneal injections of a cyclophosphamide (80 mg/kg) combination. Then AA mice were fed with nutritional supplements in a dose-dependent manner (1445.55, 963.7, 674.59 mg/kg/d) for 7 wk. At the end of the experimental period, mice were autopsied. A full blood count was performed, and femoral marrow cell suspensions were prepared to assess the total femoral nucleated cell count and the number of committed hemopoietic progenitor cells (colony-forming units). The pathologic changes of liver and spleen were analyzed.

RESULTS:

Bone Marrow Disease(s): 
Share with addtoany.com.